PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.375
Bid: 7.25
Ask: 7.50
Change: 0.00 (0.00%)
Spread: 0.25 (3.448%)
Open: 7.375
High: 7.375
Low: 7.375
Prev. Close: 7.375
IXI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TSB Grant to Develop Dementia Diagnosis Products

13 Dec 2013 07:00

RNS Number : 4517V
IXICO plc
13 December 2013
 



 

IXICO Awarded Technology Strategy Board Grant to Support the Development of Dementia Diagnosis Products

 

13 December 2013, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that it has been awarded a Stratified Medicine Grant by the UK's innovation agency, the Technology Strategy Board to provide funding to support the development of products to address the global dementia challenge.

 

The grant has been awarded under the Technology Strategy Board's recently launched 'Advancing In-Vivo Imaging for Stratified Medicine' competition. 

 

For this project, a consortium led by IXICO, which includes Imperial College, London as a research partner, Medimmune Limited (the global biologics research and development arm of AstraZeneca) and a second leading global pharmaceutical company as commercial partners, will apply a machine learning framework to a unique combination of reference data to develop a digital dementia prognosis tool. This will use commonly collected diagnostic information (including MRI scans and cognitive, functional and demographic data) to stratify patients based on their expected rate of decline. This could help with the diagnosis of dementia in the clinic and also with the enrichment of patient populations enrolled in clinical trials of investigational drugs, potentially improving the likelihood of measuring a therapeutic effect.

 

Several further global pharmaceutical companies have expressed interest joining the project as collaborators, and contributing clinical trial data in due course. The total value of the 24 month research project is approximately £1 million. The value of the grant is £633,962 of which £456,956 is allocated to IXICO and the remainder to Imperial College. The pharmaceutical partners and collaborators are contributing scientific resources from their R&D teams and access to data from completed clinical trials.

 

This brings the total grant funding secured by IXICO in the last 18 months to approximately £2.6 million of which approximately £2.4 million remains to be drawn down by IXICO.

 

This week the Technology Strategy Board features IXICO, the "Dementia Champions", as its Success Story www.innovateuk.org/success-stories detailing a funding story that stretches back 5 years.

 

Professor Derek Hill, Chief Executive of IXICO commented: "We are pleased to have been awarded this Technology Strategy Board grant. IXICO's products and services are focused on three overlapping areas within clinical trials, experimental medicine and diagnostics; the scope of this project will benefit our work in each. We look forward to working with Imperial and our commercial collaborators to develop important tools with the potential to improve clinical diagnosis of dementia and accelerate the development of effective treatments for Alzheimer's disease."

 

 

Enquiries

 

IXICO plc

+44 207 691 2064

Derek Hill, CEO

Charles Spicer, VP Corporate Development

 

Peel Hunt LLP (Nominated Adviser and broker)

+44 207 418 8900

James Steel

Vijay Barathan

Harry Florry

 

FTI Consulting Limited (U.K. Investor Relations)

+44 207 831 3113

John Dineen

Simon Conway

 

 

About IXICO

IXICO, the brain health company, was founded in 2004 with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products targeting the expanding area of imaging to inform decision-making during drug development. This has resulted in commercially successful products being launched in the clinical trials (Phase 0-III) and experimental medicine markets and being readied for launch into the wider clinical diagnostic market. Since incorporation, IXICO has been contracted by seven of the top 15 global pharmaceutical companies as well as leading biotechnology companies. In October 2013, IXICO plc was admitted to trading on AIM. More information is available on www.ixico.com

 

About the Technology Strategy Board

The Technology Strategy Board is the UK's innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit www.innovateuk.org

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCKMMMZZZRGFZZ
Date   Source Headline
29th Aug 201312:01 pmRNSSchedule 1 update - Phytopharm plc
9th Aug 20137:00 amRNSInterim Management Statement
8th Aug 201312:23 pmRNSSchedule 1 update - Phytopharm plc
8th Aug 201311:00 amRNSChange to AIM Admission Timetable
6th Aug 20132:15 pmRNSSchedule 1 - Phytopharm plc
5th Aug 20132:16 pmRNSResult of General Meeting
19th Jul 201311:06 amRNSCancellation of Listing and Admission to AIM
23rd May 20137:00 amRNSInterim Results
21st May 20137:45 amRNSStatement re. Suspension
21st May 20137:30 amRNSTemporary Suspension - Phytopharm Plc
17th May 20139:23 amRNSNotice of Results
27th Mar 201310:15 amRNSAGM Statement
26th Mar 20137:00 amRNSStrategic Review Update
15th Mar 201312:06 pmRNSHolding(s) in Company
18th Feb 20137:00 amRNSResearch Update
13th Feb 20131:59 pmRNSHolding(s) in Company
5th Feb 20137:00 amRNSInterim Management Statement
4th Feb 201311:34 amRNSNotice of AGM
19th Dec 20129:21 amRNSAnnual Financial Report
18th Dec 20127:00 amRNSCogane in ALS Update
17th Dec 201211:00 amRNSBlocklisting Interim Review
22nd Nov 20127:00 amRNSPreliminary Results
9th Nov 20121:32 pmRNSNotice of Results
5th Nov 20121:00 pmRNSBlocklisting Interim Review
17th Oct 20125:27 pmRNSBlocklisting Interim Review
1st Oct 201211:44 amRNSTotal Voting Rights
26th Sep 20127:00 amRNSHolding(s) in Company
31st Aug 20124:40 pmRNSSecond Price Monitoring Extn
31st Aug 20124:35 pmRNSPrice Monitoring Extension
29th Aug 20124:40 pmRNSSecond Price Monitoring Extn
29th Aug 20124:35 pmRNSPrice Monitoring Extension
16th Aug 20127:00 amRNSInterim Management Statement
18th Jun 20129:59 amRNSBlocklisting Interim Review
30th May 20127:00 amRNSHalf Yearly Report
11th May 20127:00 amRNSResearch Update
3rd May 201211:46 amRNSNotice of Results
3rd May 20129:54 amRNSBlocklisting Interim Review
18th Apr 20127:00 amRNSResearch Update
18th Apr 20127:00 amRNSResearch Update
11th Apr 201211:08 amRNSBlock Listing Application
29th Mar 20127:00 amRNSDirectorate Change
28th Mar 20129:35 amRNSResult of AGM
24th Feb 20127:00 amRNSNotice of AGM
16th Feb 20127:00 amRNSInterim Management Statement
14th Feb 20129:34 amRNSHolding(s) in Company
6th Feb 20129:25 amRNSAnnual Information Update
2nd Feb 20127:00 amRNSDirectorate Change
27th Jan 201210:17 amRNSAnnual Financial Report
16th Jan 20127:00 amRNSResearch Update
11th Jan 20123:53 pmRNSBlocklisting Interim Cancellation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.